Neogen Chemicals Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 8, 2025, 9:33 pm

Competitors of Neogen Chemicals Ltd

All Competitor Stocks of Neogen Chemicals Ltd

Quarterly Result

Last Updated: August 20, 2025, 6:15 am

Below is a detailed analysis of the quarterly data for Neogen Chemicals Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 185.00 Cr.. The value appears to be declining and may need further review. It has decreased from 204.00 Cr. (Mar 2025) to 185.00 Cr., marking a decrease of 19.00 Cr..
• For Expenses, as of Jun 2025, the value is 150.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 163.00 Cr. (Mar 2025) to 150.00 Cr., marking a decrease of 13.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 35.00 Cr.. The value appears to be declining and may need further review. It has decreased from 41.00 Cr. (Mar 2025) to 35.00 Cr., marking a decrease of 6.00 Cr..
• For OPM %, as of Jun 2025, the value is 19.00%. The value appears to be declining and may need further review. It has decreased from 20.00% (Mar 2025) to 19.00%, marking a decrease of 1.00%.
• For Other Income, as of Jun 2025, the value is 3.00 Cr.. The value appears strong and on an upward trend. It has increased from -11.00 Cr. (Mar 2025) to 3.00 Cr., marking an increase of 14.00 Cr..
• For Interest, as of Jun 2025, the value is 14.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 16.00 Cr. (Mar 2025) to 14.00 Cr., marking a decrease of 2.00 Cr..
• For Depreciation, as of Jun 2025, the value is 5.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 6.00 Cr. (Mar 2025) to 5.00 Cr., marking a decrease of 1.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 19.00 Cr.. The value appears strong and on an upward trend. It has increased from 8.00 Cr. (Mar 2025) to 19.00 Cr., marking an increase of 11.00 Cr..
• For Tax %, as of Jun 2025, the value is 25.00%. The value appears to be improving (decreasing) as expected. It has decreased from 33.00% (Mar 2025) to 25.00%, marking a decrease of 8.00%.
• For Net Profit, as of Jun 2025, the value is 14.00 Cr.. The value appears strong and on an upward trend. It has increased from 5.00 Cr. (Mar 2025) to 14.00 Cr., marking an increase of 9.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 5.39. The value appears strong and on an upward trend. It has increased from 1.97 (Mar 2025) to 5.39, marking an increase of 3.42.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: October 15, 2025, 4:46 am

Growth

Last Updated: September 5, 2025, 11:40 am

Balance Sheet

Last Updated: October 10, 2025, 2:37 pm

Below is a detailed analysis of the balance sheet data for Neogen Chemicals Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 26.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 26.00 Cr..
• For Reserves, as of Mar 2025, the value is 782.00 Cr.. The value appears strong and on an upward trend. It has increased from 740.00 Cr. (Mar 2024) to 782.00 Cr., marking an increase of 42.00 Cr..
• For Borrowings, as of Mar 2025, the value is 474.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 409.00 Cr. (Mar 2024) to 474.00 Cr., marking an increase of 65.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 338.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 230.00 Cr. (Mar 2024) to 338.00 Cr., marking an increase of 108.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 1,621.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,405.00 Cr. (Mar 2024) to 1,621.00 Cr., marking an increase of 216.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 228.00 Cr.. The value appears to be declining and may need further review. It has decreased from 361.00 Cr. (Mar 2024) to 228.00 Cr., marking a decrease of 133.00 Cr..
• For CWIP, as of Mar 2025, the value is 28.00 Cr.. The value appears to be declining and may need further review. It has decreased from 56.00 Cr. (Mar 2024) to 28.00 Cr., marking a decrease of 28.00 Cr..
• For Investments, as of Mar 2025, the value is 193.00 Cr.. The value appears strong and on an upward trend. It has increased from 5.00 Cr. (Mar 2024) to 193.00 Cr., marking an increase of 188.00 Cr..
• For Other Assets, as of Mar 2025, the value is 1,173.00 Cr.. The value appears strong and on an upward trend. It has increased from 983.00 Cr. (Mar 2024) to 1,173.00 Cr., marking an increase of 190.00 Cr..
• For Total Assets, as of Mar 2025, the value is 1,621.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,405.00 Cr. (Mar 2024) to 1,621.00 Cr., marking an increase of 216.00 Cr..

Notably, the Reserves (782.00 Cr.) exceed the Borrowings (474.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Neogen Chemicals Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 13.20. This value is within the healthy range. It has decreased from 13.96 (Mar 24) to 13.20, marking a decrease of 0.76.
• For Diluted EPS (Rs.), as of Mar 25, the value is 13.20. This value is within the healthy range. It has decreased from 13.96 (Mar 24) to 13.20, marking a decrease of 0.76.
• For Cash EPS (Rs.), as of Mar 25, the value is 23.66. This value is within the healthy range. It has increased from 22.11 (Mar 24) to 23.66, marking an increase of 1.55.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 299.24. It has increased from 288.21 (Mar 24) to 299.24, marking an increase of 11.03.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 299.24. It has increased from 288.21 (Mar 24) to 299.24, marking an increase of 11.03.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 294.75. It has increased from 261.82 (Mar 24) to 294.75, marking an increase of 32.93.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 53.20. This value is within the healthy range. It has increased from 44.55 (Mar 24) to 53.20, marking an increase of 8.65.
• For PBIT / Share (Rs.), as of Mar 25, the value is 42.66. This value is within the healthy range. It has increased from 35.88 (Mar 24) to 42.66, marking an increase of 6.78.
• For PBT / Share (Rs.), as of Mar 25, the value is 18.94. This value is within the healthy range. It has decreased from 19.93 (Mar 24) to 18.94, marking a decrease of 0.99.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 13.13. This value is within the healthy range. It has decreased from 13.45 (Mar 24) to 13.13, marking a decrease of 0.32.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 13.20. This value is within the healthy range. It has decreased from 13.51 (Mar 24) to 13.20, marking a decrease of 0.31.
• For PBDIT Margin (%), as of Mar 25, the value is 18.04. This value is within the healthy range. It has increased from 17.01 (Mar 24) to 18.04, marking an increase of 1.03.
• For PBIT Margin (%), as of Mar 25, the value is 14.47. This value is within the healthy range. It has increased from 13.70 (Mar 24) to 14.47, marking an increase of 0.77.
• For PBT Margin (%), as of Mar 25, the value is 6.42. This value is below the healthy minimum of 10. It has decreased from 7.61 (Mar 24) to 6.42, marking a decrease of 1.19.
• For Net Profit Margin (%), as of Mar 25, the value is 4.45. This value is below the healthy minimum of 5. It has decreased from 5.13 (Mar 24) to 4.45, marking a decrease of 0.68.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 4.47. This value is below the healthy minimum of 8. It has decreased from 5.16 (Mar 24) to 4.47, marking a decrease of 0.69.
• For Return on Networth / Equity (%), as of Mar 25, the value is 4.41. This value is below the healthy minimum of 15. It has decreased from 4.68 (Mar 24) to 4.41, marking a decrease of 0.27.
• For Return on Capital Employeed (%), as of Mar 25, the value is 11.09. This value is within the healthy range. It has increased from 10.12 (Mar 24) to 11.09, marking an increase of 0.97.
• For Return On Assets (%), as of Mar 25, the value is 1.99. This value is below the healthy minimum of 5. It has decreased from 2.43 (Mar 24) to 1.99, marking a decrease of 0.44.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.21. This value is within the healthy range. It has increased from 0.16 (Mar 24) to 0.21, marking an increase of 0.05.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.71. This value is within the healthy range. It has increased from 0.51 (Mar 24) to 0.71, marking an increase of 0.20.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.48. It has decreased from 0.54 (Mar 24) to 0.48, marking a decrease of 0.06.
• For Current Ratio (X), as of Mar 25, the value is 1.36. This value is below the healthy minimum of 1.5. It has decreased from 1.49 (Mar 24) to 1.36, marking a decrease of 0.13.
• For Quick Ratio (X), as of Mar 25, the value is 0.94. This value is below the healthy minimum of 1. It has increased from 0.76 (Mar 24) to 0.94, marking an increase of 0.18.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.46. This value is below the healthy minimum of 4. It has increased from 1.41 (Mar 24) to 1.46, marking an increase of 0.05.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 20.98 (Mar 24) to 0.00, marking a decrease of 20.98.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 12.78 (Mar 24) to 0.00, marking a decrease of 12.78.
• For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 79.02 (Mar 24) to 0.00, marking a decrease of 79.02.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 87.22 (Mar 24) to 0.00, marking a decrease of 87.22.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 2.89. This value is below the healthy minimum of 3. It has increased from 2.79 (Mar 24) to 2.89, marking an increase of 0.10.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.00. This value is below the healthy minimum of 3. It has increased from 1.84 (Mar 24) to 2.00, marking an increase of 0.16.
• For Enterprise Value (Cr.), as of Mar 25, the value is 4,637.05. It has increased from 3,527.65 (Mar 24) to 4,637.05, marking an increase of 1,109.40.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 5.96. This value exceeds the healthy maximum of 3. It has increased from 5.11 (Mar 24) to 5.96, marking an increase of 0.85.
• For EV / EBITDA (X), as of Mar 25, the value is 33.04. This value exceeds the healthy maximum of 15. It has increased from 30.02 (Mar 24) to 33.04, marking an increase of 3.02.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 5.24. This value exceeds the healthy maximum of 3. It has increased from 4.56 (Mar 24) to 5.24, marking an increase of 0.68.
• For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 79.01 (Mar 24) to 0.00, marking a decrease of 79.01.
• For Price / BV (X), as of Mar 25, the value is 5.16. This value exceeds the healthy maximum of 3. It has increased from 4.14 (Mar 24) to 5.16, marking an increase of 1.02.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 5.24. This value exceeds the healthy maximum of 3. It has increased from 4.56 (Mar 24) to 5.24, marking an increase of 0.68.
• For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness